“God’s medicine” is usually the reputation of everyone for a drug, such as the cure for hepatitis C sofebuvir, so that President Carter’s brain melanoma disappeared mysteriously PD-1 monoclonal antibody Keytruda; of course, there are those in a large number of clinical trials It has been proved that the indications are very broad and the medicines with unlimited imagination are available, such as metformin, vitamin D, adalimumab, etc.
Today, we will take a look at some of the “God’s medicine” that have many indications, annual sales of billions of dollars, and even billions of dollars.
Opdivo, Keytruda, Tecentriq
PD-1/PD-L1 inhibitors can relieve immunosuppression and activate the body’s immune system to kill tumor cells. There are already four PD-1/PD-L1 drugs on the market, including Opsivo BMS, Keytruda Merck, Tecentriq Roche, and Bavencio Pfizer/Mercury. The performance after the listing can be described in a flash.
In terms of indications, PD-1/PD-L1 is mainly developed for various solid tumors, and it is mainly used for the treatment of classical Hodgkin’s lymphoma in the field of hematological tumors. Up to now, Opdivo has been approved for 6 indications, Keytruda has been approved for 4 indications, Tecentriq has received 2 indications, and there are hundreds of clinical trials for PD-1/PD-L1 drugs. The newly approved indications will continue to increase.
Both Roche/Novartis Lucentis and Bayer/Regener’s Eylea are angiogenesis inhibitors, with the difference being that the former is a monoclonal antibody and the latter is a fusion protein. The earliest indications for both were wet age-related macular degeneration (AMD).
Lucentis has since expanded its other four ophthalmic indications, including retinal vein occlusion (RVO) macular edema, diabetic macular edema, retinopathy of DME, and myopic choroidal neovascularization. Eylea’s current number of indications is only one less than Lucentis.
In terms of market performance, Eylea surpassed Lucentis by more than five years in the evening, but its performance has been overtaking. In 2016, global sales have exceeded US$5 billion.
Bevacizumab is a recombinant humanized VEGF monoclonal antibody. It is the world’s first anti-angiogenic drug that can be widely used in many tumors. It was first approved by the FDA on February 26, 2004 for the treatment of metastatic colorectal cancer. Since then, it has expanded to many solid tumor indications such as non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical cancer, ovarian cancer, fallopian tube cancer, and peritoneal cancer. In 2016, it set a sales record of 6.783 billion Swiss francs.
Humira, Remicade, Enbrel
Humira, Remicade, and Enbrel are macromolecular biological agents that target TNFα and belong to the broad spectrum of drugs in the field of autoimmune diseases. They have many indications. Because the mechanism of action is the same, Humira is used as an example.
Humira was first approved by the FDA on December 31, 2002 for the treatment of moderately active rheumatoid arthritis, and was approved by EMA on August 9, 2003. Up to now, more than 10 indications have been approved.
From the sales point of view, Humira made great strides and reached a record high of US$16 billion in 2016. From the time of listing, Humira has achieved an accumulated sales income of US$94.5 billion.
The main ingredient of BOTOX is highly purified type A botulinum. This is a neurotransmitter blocker that relaxes overactive muscles. As its name implies, botulinum toxin is a strictly controlled “toxic drug,” but it was approved in 2002 to eliminate wrinkles on the eyebrows, which has become a beauty product that has become popular among women.
As an old product that has been on the market for more than 20 years, it is amazing that Botox’s sales revenue reached a record high of nearly US$3 billion in 2016. Successful marketing has naturally contributed to extending the vitality of Botox.
Botox’s indications also extend to preventing migraine attacks, treating urinary incontinence, and overactive bladder. On April 5th, Allergan also published the first-line results of the phase II study of Botox in the treatment of major depression, showing that Botox 30U can significantly improve the major depression scores compared with placebo at 3, 6 and 9 weeks of treatment. Botox may soon be used to treat depression.